Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferoxamine
Drug ID BADD_D00596
Description Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Indications and Usage Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
Marketing Status approved; investigational
ATC Code V03AC01
DrugBank ID DB00746
KEGG ID D03670
MeSH ID D003676
PubChem ID 2973
TTD Drug ID D0FJ8A
NDC Product Code Not Available
UNII J06Y7MXW4D
Synonyms Deferoxamine | Desferrioxamine | Desferioximine | Deferoxamine B | Desferrioxamine B | Deferoximine | Deferrioxamine B | Desferroxamine | Desferrioxamine B Mesylate | Mesylate, Desferrioxamine B | Deferoxamine Mesilate | Mesilate, Deferoxamine | Deferoxamine Mesylate | Mesylate, Deferoxamine | Deferoxamine Methanesulfonate | Methanesulfonate, Deferoxamine | Desferal
Chemical Information
Molecular Formula C25H48N6O8
CAS Registry Number 70-51-9
SMILES CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coma17.02.09.0010.001239%-
Condition aggravated08.01.03.0040.003098%-
Corneal opacity06.06.03.005---
Cough22.02.03.0010.001239%
Cyanosis02.11.04.004; 22.02.02.007; 23.06.04.005; 24.03.01.007--
Deafness04.02.01.0010.002478%-
Deafness neurosensory04.02.01.002; 17.04.07.001---
Death08.04.01.0010.016109%
Dehydration14.05.05.0010.001859%
Delusion19.10.01.001--
Depressed level of consciousness17.02.04.0020.001239%
Diabetes mellitus05.06.01.001; 14.06.01.0010.003098%-
Diarrhoea07.02.01.001--
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.001239%
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.001---
Drug hypersensitivity10.01.01.001---
Drug ineffective08.06.01.0060.011276%-
Dyspnoea02.11.05.003; 22.02.01.004--
Dysuria20.02.02.002--
Ear disorder04.03.01.001---
Eosinophilia01.02.04.001--
Erythema23.03.06.001---
Eye disorder06.08.03.0010.001859%-
Gastric ulcer haemorrhage07.04.03.005; 24.07.02.0030.001239%-
Gastroenteritis yersinia07.19.03.012; 11.02.20.002---
Gastrointestinal disorder07.11.01.001---
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.0090.001859%-
Gastrointestinal pain07.01.05.005--
Generalised tonic-clonic seizure17.12.01.002---
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages